Piperidinyl Aryloxy Propanamides and Propanoates Patent EP3759094A1
Summary
The European Patent Office published patent application EP3759094A1 for Takeda Pharmaceutical Company Limited covering piperidinyl-3-(aryloxy)propanamides and propanoates compounds. The patent application includes therapeutic indications for depression (A61P 25/24), CNS disorders (A61P 25/28), and psychiatric disorders (A61P 25/18). The application designates multiple European states including Germany, France, United Kingdom, Italy, Spain, and others.
What changed
EPO published patent application EP3759094A1 for Takeda Pharmaceutical Company Limited covering novel piperidinyl-3-(aryloxy)propanamide and propanoate compounds. The application claims compounds classified under C07D 401/14 and multiple therapeutic uses including A61P 25/24 (antidepressant), A61P 25/28 (CNS/neurodegenerative), and A61P 25/18 (psychiatric) indications. The application designates 37 European contracting states.
For pharmaceutical companies and generic drug manufacturers, this patent establishes Takeda's intellectual property protection for these specific chemical compounds and their therapeutic applications across major European markets. Competitors developing similar piperidinyl-aryloxy propanamide compounds for the indicated therapeutic uses should review the patent claims for freedom-to-operate considerations.
Archived snapshot
Apr 19, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES
Publication EP3759094A1 Kind: A1 Apr 08, 2026
Applicants
Takeda Pharmaceutical Company Limited
Inventors
CHERUVALLATH, Zacharia, GREEN, Jason, JOHNSON, Ben, SCHLEICHER, Kristin, SUN, Huikai, TANG, Mingnam
IPC Classifications
C07D 401/14 20060101AFI20190907BHEP C07D 401/12 20060101ALI20190907BHEP C07D 491/048 20060101ALI20190907BHEP C07D 207/14 20060101ALI20190907BHEP C07D 211/58 20060101ALI20190907BHEP A61P 25/24 20060101ALI20190907BHEP A61P 25/28 20060101ALI20190907BHEP A61P 25/18 20060101ALI20190907BHEP A61K 31/44 20060101ALI20190907BHEP A61K 31/444 20060101ALI20190907BHEP A61K 31/4439 20060101ALI20190907BHEP A61K 31/506 20060101ALI20190907BHEP A61K 31/4355 20060101ALI20190907BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.